Aldeyra Therapeutics(ALDX)

4.69 -0.12 -2.4948%

今开：4.81	昨收：4.81
最高：4.84	最低：4.525
涨停价：0.0	跌停价：0.0
总市值：2.82163405E8

Aldeyra Therapeutics的热门讨论

OYang10-28 19:28

#药闻简讯# $Aldeyra Therapeutics(ALDX)$ 宣布酒精性肝炎二期临床试验结果积极，聚焦下一代分子 RASP 产品候选管线
相对于基线，用于酒精相关肝病的信号发现分子 ADX‑629 在肝功能方面显示出统计学上的显著改善
ADX-629，一种用于概念验证临床试验的信号发现 RASP 调节剂，在一项针对四...查看全文

OYang08-28 22:22

#药闻简讯# $Aldeyra Therapeutics(ALDX)$ 获得欧洲药品管理局对 ADX-2191 用于治疗免疫特权部位原发性大 B 细胞淋巴瘤的孤儿药认定，包括原发性视网膜脉络膜淋巴瘤查看全文

OYang08-19 21:41

#药闻简讯# $Aldeyra Therapeutics(ALDX)$ 公司获得ADX-2191治疗视网膜色素变性的快速通道指定。查看全文

持股变动声明

Aldeyra Therapeutics(ALDX)08-16 04:15

$Aldeyra Therapeutics(ALDX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-25-109391 Size: 4 KB 网页链接查看全文

季度财报

Aldeyra Therapeutics(ALDX)11-06 05:25

$Aldeyra Therapeutics(ALDX)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001193125-25-266989 Act: 34 Size: 8 MB 网页链接查看全文

持股变动声明

Aldeyra Therapeutics(ALDX)08-14 06:05

$Aldeyra Therapeutics(ALDX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-25-108210 Size: 5 KB 网页链接查看全文

其他

Aldeyra Therapeutics(ALDX)08-15 04:35

$Aldeyra Therapeutics(ALDX)$ SCHEDULE 13G/A [Amend] Statement of Beneficial Ownership by Certain Investors Accession Number: 0000950170-25-108920 Act: 34 Size: 10 KB 网页链接查看全文

当期报告

Aldeyra Therapeutics(ALDX)08-19 19:05

$Aldeyra Therapeutics(ALDX)$ 8-K Current report, item 9.01 Accession Number: 0000950170-25-109932 Act: 34 Size: 275 KB 网页链接查看全文

证券出售报告

Aldeyra Therapeutics(ALDX)08-13 05:55

$Aldeyra Therapeutics(ALDX)$ 144 Report of proposed sale of securities Accession Number: 0001836354-25-000003 Act: 33 Size: 4 KB 网页链接查看全文

当期报告

Aldeyra Therapeutics(ALDX)10-28 19:05

$Aldeyra Therapeutics(ALDX)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001193125-25-252200 Act: 34 Size: 486 KB 网页链接查看全文

Aldeyra Therapeutics的最新讨论

Aldeyra Therapeutics(ALDX)2020-04-28 05:30

$Aldeyra Therapeutics(ALDX)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001564590-20-018879 Act: 34 Size: 461 KB 网页链接查看全文

Aldeyra Therapeutics(ALDX)2020-04-28 05:05

$Aldeyra Therapeutics(ALDX)$ DEF 14A Other definitive proxy statements Accession Number: 0001564590-20-018862 Act: 34 Size: 1 MB 网页链接查看全文

肖恩大侠2020-04-16 00:38

$Aldeyra Therapeutics(ALDX)$ Potential of ADX-629 in COVID-19 lifts Aldeyra, up 14% premarket
Apr. 14, 2020 9:23 AM ET|About: Aldeyra Therapeutics, ... (ALDX)|By: Douglas W. House, SA News Editor
Thinly traded nano cap Aldeyra Therapeutics (NASDAQ:ALDX) is up 14% prem...查看全文

Aldeyra Therapeutics(ALDX)2020-04-14 20:30

$Aldeyra Therapeutics(ALDX)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001193125-20-105860 Act: 34 Size: 42 KB 网页链接查看全文

Aldeyra Therapeutics(ALDX)2020-03-18 04:45

$Aldeyra Therapeutics(ALDX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000899243-20-008616 Size: 4 KB 网页链接查看全文

chuminhua2020-03-13 18:04

3/12，Aldeyra Therapeutics$Aldeyra Therapeutics(ALDX)$ 决定暂停两个药物的临床开发，以维持其现金流至年底。暂停的项目包括2018年开始的小分子RASP抑制剂reproxalap皮肤制剂治疗Sjogren-Larsson综合征的III期研究，以及热休克蛋白90的抑制剂ADX-1612原计划Q4进入的移植后淋巴增生综合症II期研...查看全文

Aldeyra Therapeutics(ALDX)2020-03-13 05:00

$Aldeyra Therapeutics(ALDX)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0001193125-20-071672 Act: 33 Size: 48 KB 网页链接查看全文

Aldeyra Therapeutics(ALDX)2020-03-13 04:40

$Aldeyra Therapeutics(ALDX)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001564590-20-010493 Act: 34 Size: 8 MB 网页链接查看全文

Aldeyra Therapeutics(ALDX)2020-03-12 19:40

$Aldeyra Therapeutics(ALDX)$ 8-K Current report, items 2.02, 5.02, 8.01, and 9.01 Accession Number: 0001193125-20-070920 Act: 34 Size: 114 KB 网页链接查看全文

Aldeyra Therapeutics(ALDX)2020-03-07 05:50

$Aldeyra Therapeutics(ALDX)$ 4/A [Amend] Statement of changes in beneficial ownership of securities Accession Number: 0000899243-20-007447 Size: 8 KB 网页链接查看全文

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46

Aldeyra Therapeutics的新闻

Aldeyra Therapeutics2025财年年报业绩会议总结

一、开场介绍会议时间：未明确提及具体日期
主持人说明：会议为HC Wainwright全球投资会议，由该公司资深生物技术分析师Matthew Caufield主持，目的是与Aldeyra Therapeutics公司CEO Todd Brady讨论公司管线进展。
管理层发言摘要： Todd Brady（CEO）：重点介绍了公司主要候...